On Thursday, Viking Therapeutics (NASDAQ:VKTX) received a favorable initiation of coverage from Jefferies, with a Buy rating and a price target set at $110.00. The... Biotech firm Viking ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

Investing.com - Viking Therapeutics Inc (NASDAQ: VKTX) reported first quarter EPS of $-0.250, $0.01 worse than the analyst estimate of $-0.240. Revenue for the quarter came in at ...

The chart below shows the one year performance of VKTX shares: Looking at the chart above, VKTX's low point in its 52 week range is $20.28 per share, with $99.41 as the 52 week high point — that ...

The stock also underperformed the broader Medical sector and the S&P 500 during this timeframe, as shown in the chart below. VKTX’s shares are currently trading below the 50 and 200-day moving ...

Shares of Viking Therapeutics VKTX have lost nearly 22% in the past six months, significantly underperforming the industry’s 5.3% decline. The stock also underperformed the broader Medical sector and ...